ArticleFrontiers in oncology2026

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Marcia S Brose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.